Author Interviews, Infections, Pharmaceutical Companies / 08.07.2019
Synthetic Cannabidiol Explored As Potential Topical Antibiotic
MedicalResearch.com Interview with:
[caption id="attachment_50138" align="alignleft" width="150"]
Dr. Blaskovich[/caption]
Dr Mark Blaskovich PhD
Institute for Molecular Bioscience's Centre for Superbug Solutions
The University of Queensland
In collaboration with Botanix Pharmaceuticals Ltd
MedicalResearch.com: What is the background for this study?
Response: Botanix is a company that has been developing topical formulations of CBD for treatment of skin diseases such as atopic dermatitis and acne, based on its reported anti-inflammatory properties. However, these diseases are also associated with bacterial infection, so they were interested in looking at potential antimicrobial activity, as there are some previous literature reports suggesting it is active. They contacted us to do some more in-depth investigations.
Dr. Blaskovich[/caption]
Dr Mark Blaskovich PhD
Institute for Molecular Bioscience's Centre for Superbug Solutions
The University of Queensland
In collaboration with Botanix Pharmaceuticals Ltd
MedicalResearch.com: What is the background for this study?
Response: Botanix is a company that has been developing topical formulations of CBD for treatment of skin diseases such as atopic dermatitis and acne, based on its reported anti-inflammatory properties. However, these diseases are also associated with bacterial infection, so they were interested in looking at potential antimicrobial activity, as there are some previous literature reports suggesting it is active. They contacted us to do some more in-depth investigations.
